Why is Corcept Therapeutics stock tumbling today?
Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.
How this was made
The 30-second read
Why it matters
Genmab's Phase 3 success introduces a direct competitor, prompting a sharp price correction for Corcept.
Market read
The news explains a significant intra‑day decline in Corcept's stock, offering a clear trading signal.
What to watch
Potential upcoming data from Corcept's own trials or a strategic acquisition could mitigate the competitive threat.
Background
Corcept Therapeutics' Lifyorli was FDA‑approved earlier in 2026 for platinum‑resistant ovarian cancer and has been a key growth driver.
Ticker impact
Corcept Therapeutics shares fell 12.9% after Genmab announced positive Phase 3 results that directly challenge Corcept's approved ovarian‑cancer drug.
likely further downside as investors reassess market share and revenue outlook
A rival's pivotal trial data directly undermines Corcept's core product, driving a sharp intra‑day sell‑off.
Market effects
Oncology biotech sector may see broader re‑rating as competitive trial data emerge.
U.S. biotech stocks could face heightened volatility in the afternoon session.
Limited to U.S. and European investors tracking ovarian‑cancer therapeutics.
Counterpoint
If Corcept can quickly expand Lifyorli's indication or secure new partnerships, the sell‑off may be over‑stated.
Key entities
- companyCorcept Therapeutics
US‑listed biotech (ticker CORT) with FDA‑approved ovarian‑cancer drug.
- companyGenmab
Rival biopharma announcing positive Phase 3 trial results.
